Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

International Randomised Controlled Trial evaluating metabolic syndrome in type 2 Diabetic Cigarette Smokers following switching to Combustion-Free Nicotine Delivery Systems: the DIASMOKE protocol

Arkadiusz Krysiński, Cristina Russo, Sarah John, Jonathan Belsey, Davide Campagna, Pasquale Caponnetto, Lorina Vudu, Chong Wei Lim, Francesco Purrello, Maurizio Di Mauro, Farrukh Iqbal, David Fluck, Edward Franek, View ORCID ProfileRiccardo Polosa, Pankaj Sharma on behalf of the DIASMOKE collaborators
doi: https://doi.org/10.1101/2020.08.19.20177253
Arkadiusz Krysiński
1Mossakowski Clinical Research Centre, Polish Academy of Sciences, Warsaw, Poland
2Department of Internal Diseases, Endocrinology and Diabetology, Central Clinical Hospital MSWiA, Warsaw, Poland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Cristina Russo
3Ashford and St. Peter’s NHS Foundation Trust, Surrey, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sarah John
4Murray Edwards College, University of Cambridge, Cambridge, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jonathan Belsey
5JB Medical Ltd, Sudbury, Suffolk, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Davide Campagna
6U.O.C. MCAU, University Teaching Hospital “Policlinico-Vittorio Emanuele”, University of Catania, Catania, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Pasquale Caponnetto
7Centro per la Prevenzione e Cura del Tabagismo (CPCT), University Teaching Hospital “Policlinico-Vittorio Emanuele”, University of Catania, Catania, Italy
8Center of Excellence for the Acceleration of HArm Reduction (CoEHAR), University of Catania, Catania, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lorina Vudu
9Department of Endocrinology, “Nicolae Testemițanu” State University of Medicine and Pharmacy, Chisinau, Republic of Moldova
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Chong Wei Lim
3Ashford and St. Peter’s NHS Foundation Trust, Surrey, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Francesco Purrello
8Center of Excellence for the Acceleration of HArm Reduction (CoEHAR), University of Catania, Catania, Italy
10Department of Clinical and Experimental Medicine, University of Catania, Catania, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Maurizio Di Mauro
8Center of Excellence for the Acceleration of HArm Reduction (CoEHAR), University of Catania, Catania, Italy
10Department of Clinical and Experimental Medicine, University of Catania, Catania, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Farrukh Iqbal
11College of Medicine, University of Lahore, Lahore, Pakistan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David Fluck
3Ashford and St. Peter’s NHS Foundation Trust, Surrey, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Edward Franek
1Mossakowski Clinical Research Centre, Polish Academy of Sciences, Warsaw, Poland
2Department of Internal Diseases, Endocrinology and Diabetology, Central Clinical Hospital MSWiA, Warsaw, Poland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Riccardo Polosa
8Center of Excellence for the Acceleration of HArm Reduction (CoEHAR), University of Catania, Catania, Italy
10Department of Clinical and Experimental Medicine, University of Catania, Catania, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Riccardo Polosa
Pankaj Sharma
3Ashford and St. Peter’s NHS Foundation Trust, Surrey, UK
12Institute of Cardiovascular Research, Royal Holloway, University of London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: pankaj.sharma@rhul.ac.uk
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

ABSTRACT

Reducing exposure to cigarette smoke is an imperative for public health, and even more so for diabetic patients. Increasingly, combustion-free technologies for nicotine delivery such as e-cigarettes and heated tobacco products are substituting conventional cigarettes and accelerating the current downward trends in smoking prevalence. However, there is limited information about the long-term health impact in diabetics who use these technologies.

This international randomised controlled trial of type 2 diabetic cigarette smokers will test the hypothesis that following a switch from conventional cigarettes to Combustion-Free Nicotine Delivery Systems (C-F NDS), a measurable improvement in metabolic syndrome (MetS) risk factors and functional parameters will be shown over the course of 2 years.

A total of 576 patients will be randomized (1:2 ratio) to either a control arm (Study Arm A), in which they will be offered referral to smoking cessation programs or to an intervention arm (Study Arm B), in which they will be assigned to C-F NDS use. The primary outcome will be the prevalence of the a difference in MetS score between baseline and 2 years follow-up, with comparison being made between diabetic patients randomized to each arm of the study. Patient recruitment will start in October 2020 and enrolment is expected to be completed by August 2021.

This will be the first study determining the overall health impact of using such technologies in diabetic patients. Data from this study will provide valuable insights into the overall potential of C-F NDS to reduce the risk of cardiovascular disease in individuals, particularly diabetic patients.

Clinical Trial Registration: https://clinicaltrials.gov/ct2/show/NCT04231838

Competing Interest Statement

Dr. Russo has received honoraria for speaking and financial support to attend meetings/ advisory boards from Novo Nordisk, Sanofi,and Novartis. CR has also served as a consultant for Novo Nordisk and Medtronic. Dr. Belsey reports payments made from Metanoic Health Ltd, for statistical support in the design and conduct of the study; Dr. Polosa is full-time employee of the University of Catania, Italy. In relation to his work in the area of tobacco control and respiratory diseases, RP has received lecture fees and research funding from Pfizer, GlaxoSmithKline, CV Therapeutics, NeuroSearch A/S, Sandoz, MSD, Boehringer Ingelheim, Novartis, Duska Therapeutics, and Forest Laboratories. He has also served as a consultant for Pfizer, Global Health Alliance for treatment of tobacco dependence, CV Therapeutics, NeuroSearch A/S, Boehringer Ingelheim, Novartis, Duska Therapeutics, Alfa-Wassermann, Forest Laboratories, ECITA (Electronic Cigarette Industry Trade Association, in the UK), Arbi Group Srl., and Health Diplomats. RP is the Founder of the Center of Excellence for the acceleration of Harm Reduction at the University of Catania (CoEHAR), which has received a grant from Foundation for a Smoke Free World to develop and carry out 8 research projects. RP is also currently involved in the following pro bono activities: scientific advisor for LIAF, Lega Italiana Anti Fumo (Italian acronym for Italian Anti-Smoking League) and Chair of the European Technical Committee for standardization on Requirements and test methods for emissions of electronic cigarettes (CEN/TC 437; WG4). All other authors have no relevant conflict of interest to declare in relation to this study.

Clinical Trial

NCT04231838

Funding Statement

ECLAT srl, a research spin off company of the University of Catania is the Sponsor of DIASMOKE.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

IRAS project ID:280909 Protocol number: COE1-05-DIASMOKE 2.0 REC reference: 20/LO/0704

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

The data that support the findings of this study are available from the corresponding author, PS, upon reasonable request.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Back to top
PreviousNext
Posted August 22, 2020.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
International Randomised Controlled Trial evaluating metabolic syndrome in type 2 Diabetic Cigarette Smokers following switching to Combustion-Free Nicotine Delivery Systems: the DIASMOKE protocol
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
International Randomised Controlled Trial evaluating metabolic syndrome in type 2 Diabetic Cigarette Smokers following switching to Combustion-Free Nicotine Delivery Systems: the DIASMOKE protocol
Arkadiusz Krysiński, Cristina Russo, Sarah John, Jonathan Belsey, Davide Campagna, Pasquale Caponnetto, Lorina Vudu, Chong Wei Lim, Francesco Purrello, Maurizio Di Mauro, Farrukh Iqbal, David Fluck, Edward Franek, Riccardo Polosa, Pankaj Sharma
medRxiv 2020.08.19.20177253; doi: https://doi.org/10.1101/2020.08.19.20177253
Reddit logo Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
International Randomised Controlled Trial evaluating metabolic syndrome in type 2 Diabetic Cigarette Smokers following switching to Combustion-Free Nicotine Delivery Systems: the DIASMOKE protocol
Arkadiusz Krysiński, Cristina Russo, Sarah John, Jonathan Belsey, Davide Campagna, Pasquale Caponnetto, Lorina Vudu, Chong Wei Lim, Francesco Purrello, Maurizio Di Mauro, Farrukh Iqbal, David Fluck, Edward Franek, Riccardo Polosa, Pankaj Sharma
medRxiv 2020.08.19.20177253; doi: https://doi.org/10.1101/2020.08.19.20177253

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Endocrinology (including Diabetes Mellitus and Metabolic Disease)
Subject Areas
All Articles
  • Addiction Medicine (239)
  • Allergy and Immunology (521)
  • Anesthesia (124)
  • Cardiovascular Medicine (1418)
  • Dentistry and Oral Medicine (217)
  • Dermatology (158)
  • Emergency Medicine (291)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (582)
  • Epidemiology (10288)
  • Forensic Medicine (6)
  • Gastroenterology (527)
  • Genetic and Genomic Medicine (2625)
  • Geriatric Medicine (254)
  • Health Economics (496)
  • Health Informatics (1729)
  • Health Policy (789)
  • Health Systems and Quality Improvement (671)
  • Hematology (266)
  • HIV/AIDS (564)
  • Infectious Diseases (except HIV/AIDS) (12083)
  • Intensive Care and Critical Care Medicine (648)
  • Medical Education (273)
  • Medical Ethics (83)
  • Nephrology (288)
  • Neurology (2456)
  • Nursing (144)
  • Nutrition (377)
  • Obstetrics and Gynecology (491)
  • Occupational and Environmental Health (566)
  • Oncology (1319)
  • Ophthalmology (400)
  • Orthopedics (146)
  • Otolaryngology (235)
  • Pain Medicine (168)
  • Palliative Medicine (51)
  • Pathology (342)
  • Pediatrics (778)
  • Pharmacology and Therapeutics (329)
  • Primary Care Research (296)
  • Psychiatry and Clinical Psychology (2394)
  • Public and Global Health (4999)
  • Radiology and Imaging (893)
  • Rehabilitation Medicine and Physical Therapy (525)
  • Respiratory Medicine (681)
  • Rheumatology (309)
  • Sexual and Reproductive Health (255)
  • Sports Medicine (244)
  • Surgery (297)
  • Toxicology (45)
  • Transplantation (140)
  • Urology (108)